Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 11/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 4/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508857 | 0.93 | BACE1 (0.40) | BACE1BACE2CYP3A4CTSDMEN1 | |
| SCHEMBL4218556 | 0.93 | BACE1 (0.40) | BACE1BACE2CYP3A4CTSDMEN1 | |
| SCHEMBL4213633 | 0.93 | BACE1 (0.40) | BACE1BACE2CYP3A4CTSDMEN1 | |
| SCHEMBL3510514 | 0.92 | BACE1 (0.39) | BACE1BACE2CYP3A4CTSD | |
| SCHEMBL4218451 | 0.92 | BACE1 (0.40) | BACE1BACE2CYP3A4CTSD | |
| SCHEMBL4204589 | 0.92 | BACE1 (0.40) | BACE1BACE2CYP3A4CTSD | |
| SCHEMBL3511560 | 0.92 | BACE1 (0.39) | CCR1BACE1BACE2CYP3A4CTSD | |
| SCHEMBL3509367 | 0.92 | BACE1 (0.39) | BACE1BACE2CYP3A4CTSDMEN1 | |
| SCHEMBL4208737 | 0.91 | BACE1 (0.41) | CCR1BACE1BACE2CYP3A4CTSD | |
| SCHEMBL3510454 | 0.91 | BACE1 (0.41) | BACE1BACE2CYP3A4CTSDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | CCR1 4849/4885BACE1 1/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.